474 filings
Page 5 of 24
8-K
9zx qq16nlh1ij6d5u5
12 Aug 21
NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights
4:18pm
EFFECT
a14ysg mtlkofr
8 Jul 21
Notice of effectiveness
12:15am
424B3
rjt4mzzz
7 Jul 21
Prospectus supplement
5:16pm
DEFA14A
tzgfc1
2 Jul 21
Additional proxy soliciting materials
7:06am
CORRESP
rvq uldkn
2 Jul 21
Correspondence with SEC
12:00am
UPLOAD
qn2z zsmwgirydjat
1 Jul 21
Letter from SEC
12:00am
8-K
05inp66
8 Jun 21
Regulation FD Disclosure
2:01pm
8-K
db2k85e
25 May 21
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer
9:00am
8-K
cvsohk gm1z6p81d
20 May 21
NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer
9:00am
8-K
epvtye1p
13 May 21
NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021
4:32pm
8-K
vpbeq9079vaxkp73
12 May 21
NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors
4:30pm
8-K
l6o26jf
30 Apr 21
Other Events
5:01pm
8-K
hm1l8q31yqb
27 Apr 21
Entry into a Material Definitive Agreement
7:30am
8-K
eavnr2jkt 38r
26 Apr 21
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:11pm
424B5
9rlnlc8t36ymc3x6x71
23 Apr 21
Prospectus supplement for primary offering
4:05pm
8-K
5ybgr69r
22 Apr 21
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
9:33am